Should Pfizer Buy Biogen? No.
641760
It wouldn't be good for either company. Here's why.
607613
Genzyme Corp. said it completed its $345 million acquisition of Bioenvision Inc. despite complaints by some Bioenvision shareholders the price the Cambridge biotech offered was too low. Genzyme initially tried to take control of the New York biotech through a tender offer, but managed to acquire only 22 percent of shares that way. Bioenvision then tried to persuade a majority ...
453963
The bureau has abandoned its custom-made internet surveillance technology. Also:  Intel lets their new chips fall where they may, for a profit & hellip;.  Despite fallbacks, Pfizer's revenue is still on the rise & hellip; and more.
214879
DUBLIN -- US drug company Biogen Idec is considering an all-share bid of more than 8.5 billion euros ($10.6 billion) for Irish peer Elan , a newspaper reported yesterday.
646974
Peter Kellogg , chief financial officer at Biogen Idec Inc. for the past seven years, resigned to take a similar post at Merck &amp; Co., the New Jersey pharmaceutical giant. Merck dwarfs Biogen Idec, with 2006 sales of $22.6 billion, compared with the Cambridge company's $2.6 billion. Kellogg will leave Biogen Idec Aug. 10, and the company said ...
82032
To turn its new multiple sclerosis treatment Antegren into a blockbuster drug with more than $1 billion in annual sales, Biogen Idec and its partner, Elan Pharmaceuticals, might not have to persuade doctors that it is superior to existing interferon treatments. Partial data released by the companies appear to confirm the treatment's outstanding clinical performance.
550692
NEW YORK - Today at the UBS Global Life Sciences Conference, AtheroGenics was met with pointed skepticism over trial results for its drug, AGI-1067.
287487
The U.S. government declined on  Thursday to allow a nonprofit company to sell cheaper, generic  versions of a blockbuster Pfizer Inc. drug for treating  glaucoma.
170801
Who'sgot money riding on the outcome of the great pharmaceuticals debate? You and I do, if we have our retirement accounts invested in any of the hordes of mutual funds that own shares of Pfizer Inc. , Eli Lilly &amp; Co., Schering-Plough Corp. , and other titans of the medication trade.
232138
MGI Pharma Inc. MOGN.O will spend up  to $85 million for a stake in SuperGen Inc. SUPG.O and global  rights to develop and sell SuperGen's experimental drug for an  often-fatal cancer of the bone marrow, the companies said on  Wednesday.
172344
Shareholders want a higher price on MetaSolv. Don't count on it.
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.
768157
Biogen presents at the JPMorgan Healthcare Conference.
320067
A drug launch is not driving share price increases for Indevus.
507775
By Tricia Bishop, The Baltimore Sun  Dec. 14--One of MedImmune Inc.'s major shareholders is urging the state's flagship biotech to put itself up for sale, suggesting management hasn't made the most from its assets, which include four products on the market and about 40 in the pipeline.
184248
Averse to risk? Check out these nontraditional drug companies.
515226
A federal judge denied a request by Pfizer (nyse: PFE - news - people ) to halt competitors&#39; sales of gabapentin, a generic form of Pfizer&#39;s Neurontin epilepsy drug.